OTCMKTS:KHTRF Knight Therapeutics (KHTRF) Stock Price, News & Analysis $7.48 -0.10 (-1.33%) As of 03:54 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and Trends About Knight Therapeutics Stock (OTCMKTS:KHTRF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Knight Therapeutics alerts:Sign Up Key Stats Today's Range$7.48▼$7.5150-Day Range$6.67▼$7.5952-Week Range$4.07▼$7.63Volume1,650 shsAverage Volume7,501 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview Knight Therapeutics Inc. is a Canadian specialty pharmaceutical company focused on acquiring, licensing, commercializing and, in some cases, developing innovative prescription medicines. The company targets areas of significant unmet medical need, including oncology, rare diseases, neurology, infectious diseases and other specialty-care markets. Knight works with pharmaceutical and biotechnology partners to bring approved or late-stage therapies to patients. Its activities generally include regulatory support, market access, commercialization and distribution rather than large-scale discovery research. The company has also pursued opportunities involving specialty medicines and medical products in international markets. Founded in 2014 by Jonathan Goodman, who previously founded Paladin Labs, Knight is headquartered in Montreal, Quebec. Through its Canadian operations and international subsidiaries and partnerships, the company serves healthcare markets in Canada and selected countries in Latin America and other regions. Goodman has served as the company's president and chief executive officer.AI Generated. May Contain Errors. Read More Receive KHTRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KHTRF Stock News HeadlinesKnight Therapeutics Announces Regulatory Approval of NIKTIMVO® in BrazilOctober 6, 2026 | financialpost.comFKnight Therapeutics Inc. places No. 345 on The Globe and Mail’s eighth annual ranking of Canada’s Top Growing CompaniesSeptember 25, 2026 | financialpost.comFHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 14 at 1:00 AM | Banyan Hill Publishing (Ad)Knight Therapeutics Announces Regulatory Submission of GEMTESA® in CanadaSeptember 15, 2026 | financialpost.comFKnight Therapeutics Announces Regulatory Submission of GEMTESA® in CanadaSeptember 15, 2026 | globenewswire.comKnight Therapeutics Inc KHTRFSeptember 10, 2026 | morningstar.comMKnight Therapeutics Announces Regulatory Approval of TAVALISSE® in ColombiaSeptember 1, 2026 | financialpost.comFKnight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in BrazilAugust 27, 2026 | financialpost.comFSee More Headlines KHTRF Stock Analysis - Frequently Asked Questions How have KHTRF shares performed this year? Knight Therapeutics' stock was trading at $4.3765 at the start of the year. Since then, KHTRF shares have increased by 71.0% and is now trading at $7.4840. How do I buy shares of Knight Therapeutics? Shares of KHTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/14/2026Next Earnings (Estimated)11/05/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:KHTRF CIKN/A Webwww.knighttx.com Phone(514) 484-4483FaxN/AEmployees830Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:KHTRF) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
